Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Santaris, GSK partner to develop RNA antagonists

Santaris (Horsholm, Denmark) and GlaxoSmithKline (LSE:GSK; GSK) partnered to discover, develop and commercialize RNA antagonists as antivirals. Santaris will be

Read the full 204 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE